4 July 2023: Reference is made to the stock exchange release of Vistin Pharma ASA (“Vistin” or the “Company”) dated 30 June 2023 at 07:30 hours CEST concerning an offer to buy back shares (the “Offer”) in connection with its Long Term Incentive Plan (LTIP) for the executive management. The Offer expired Monday 3 July 2023 at 16:00 hours CEST.
The Company has resolved to buy back 220 000 shares at a price of NOK 23,00 per share (the “Purchase Price”). The Purchase Price was determined through a reverse book-building process conducted by SpareBank 1 Markets AS.
As a result of the buy back, the Company owns 220 000 own shares, corresponding to 0,50% of the share capital and voting rights in the Company.
For further information, please contact:
Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at…
LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…
Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…
Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…
Independent analysis examines why 'natural Ozempic alternative' and 'berberine weight loss patch' searches are driving…